bluuebunny/crossref_metadata_2025 huggingface dataset:
Resonance enhancement of the electromagnetic interaction between two charged particles in the bound state in the continuum
Authors: Agafonov A. I.
Published: August 2023

In bound states in the continuum (BIC) the mass of a composite particle is greater than the total mass of its constituents. The BIC state is investigated in a system of two charged particles [Formula: see text] and [Formula: see text] with different masses ([Formula: see text]), using the ladder Bethe–Salpeter equation. We demonstrate that there are two momentum space regions for the positive binding energy, in which the electromagnetic interaction between the particles is strongly enhanced, and the effective coupling constant turns out to be equal to [Formula: see text], where [Formula: see text] is the fine structure constant. The interaction resonance confines the constituents in the BIC state with the positive binding energy, which is of the order of the mass of the lighter particle from this pair.
BERD+: A Generic Sequential Recommendation Framework by Eliminating Unreliable Data with Item- and Attribute-level Signals
Authors: Sun Yatong , Yang Xiaochun , Sun Zhu , Wang Bin
Published: August 2023

Most sequential recommendation systems (SRSs) predict the next item as the target for users given its preceding items as input, assuming the target is definitely related to its input. However, users may unintentionally click items that are inconsistent with their preference due to external factors, causing unreliable instances whose target mismatches the input. We,
for the first time
, verify SRSs can be misguided by such unreliable instances and design a generic SRS framework
B
y
E
liminating un
R
eliable
D
ata (BERD+), which can be flexibly plugged into existing SRSs. Specifically, BRED+ is guided with observations on the training process of instances: Unreliable instances generally have high training loss; high-loss instances are not necessarily unreliable but uncertain ones caused by blurry sequential patterns; and item attributes help rectify instance loss and uncertainty, but may also introduce disturbance. Accordingly, BERD+ models both the loss and uncertainty of each instance via a Gaussian distribution, whereby a heterogeneous uncertainty-aware graph convolution network is designed to learn accurate embeddings for different entities while reducing the disturbance caused by uncertain attribute values. Thereafter, an explicit preference extractor rectifies instance loss and uncertainty and reduces the disturbance caused by less-focused attribute types. Finally, instances with high loss and low uncertainty are eliminated as unreliable data. Extensive experiments verify the efficacy of BERD+.
Near-Optimal Time–Energy Tradeoffs for Deterministic Leader Election
Authors: Chang Yi-Jun , Duan Ran , Jiang Shunhua
Published: August 2023

We consider the energy complexity of the leader election problem in the single-hop radio network model, where each device
v
has a unique identifier
ID
(
v
) ∈{ 1, 2, ⋖ ,
N
} . Energy is a scarce resource for small battery-powered devices. For such devices, most of the energy is often spent on communication, not on computation. To approximate the actual energy cost, the energy complexity of an algorithm is defined as the maximum over all devices of the number of time slots where the device transmits or listens.

Much progress has been made in understanding the energy complexity of leader election in radio networks, but very little is known about the tradeoff between time and energy. Chang et al. [STOC 2017] showed that the optimal deterministic energy complexity of leader election is Θ (log log
N
) if each device can simultaneously transmit and listen but still leaving the problem of determining the optimal time complexity under any given energy constraint.

Time–energy tradeoff:
For any
k
≥ log log
N
, we show that a leader among at most
n
devices can be elected deterministically in
O
(
k
ċ
n
1+ε
) +
O
(
k
ċ
N
1/k
) time and
O
(
k
) energy if each device can simultaneously transmit and listen, where ε > 0 is any small constant. This improves upon the previous
O
(
N
)-time
O
(log log
N
)-energy algorithm by Chang et al. [STOC 2017]. We provide lower bounds to show that the time–energy tradeoff of our algorithm is near-optimal.

Dense instances:
For the dense instances where the number of devices is
n
= Θ (
N
), we design a deterministic leader election algorithm using only
O
(1) energy. This improves upon the
O
(log*
N
)-energy algorithm by Jurdziński, Kutyłowski, and Zatopiański [PODC 2002] and the
O
(α (
N
))-energy algorithm by Chang et al. [STOC 2017]. More specifically, we show that the optimal deterministic energy complexity of leader election is

\(\Theta (\max \lbrace 1, \log \tfrac{N}{n}\rbrace)\)

if each device cannot simultaneously transmit and listen, and it is

\(Θ (\max \lbrace 1, \log \log \tfrac{N}{n}\rbrace)\)

if each device can simultaneously transmit and listen.
airBP: Monitor Your Blood Pressure with Millimeter-Wave in the Air
Authors: Liang Yumeng , Zhou Anfu , Wen Xinzhe , Huang Wei , Shi Pu , Pu Lingyu , Zhang Huanhuan , Ma Huadong
Published: August 2023

Blood pressure (BP), an important vital sign to assess human health, is expected to be monitored conveniently. The existing BP monitoring methods, either traditional cuff based or newly emerging wearable based, all require skin contact, which may cause unpleasant user experience and is even injurious to certain users. In this article, we explore contactless BP monitoring and propose airBP, which emits millimeter-wave signals toward a user’s wrist, and captures the reflected signal bounded off from the pulsating artery underlying the wrist. By analyzing the reflected signal strength of the signal, airBP generates the arterial pulse and further estimates BP by exploiting the relationship between the arterial pulse and BP. To realize airBP, we design a new beam-forming method to keep focusing on the tiny and hidden wrist artery, by leveraging the inherent periodicity of the arterial pulse. Moreover, we custom design a pre-training and neural network architecture, to combat the challenges from the arterial pulse sparsity and ambiguity, so as to estimate BP accurately. We prototype airBP using a coin-size commercial off-the-shelf millimeter-wave radar and perform extensive experiments on 41 subjects. The results demonstrate that airBP accurately estimates systolic and diastolic BP, with a mean error of –0.30 mmHg and –0.23 mmHg, as well as a standard deviation error of 4.80 mmHg and 3.79 mmHg (within the acceptable range regulated by the FDA’s AAMI protocol), respectively, at a distance up to 26 cm.
Pest Elaterids of North America: New Insights and Opportunities for Management
Authors: Rashed Arash , van Herk Willem G.
Published: August 2023

The larval stages of click beetle (Coleoptera: Elateridae) species, several of which are serious agricultural pests, are called wireworms. Their cryptic subterranean habitat, resilience, among-species differences in ecology and biology, and broad host range, as well as the lack of objective economic injury thresholds, have rendered wireworms a challenging pest complex to control. Significant progress has been made in recent years, introducing a new effective class of insecticides and improving species identification and our understanding of species-specific phenology, chemical ecology (i.e., adult sex pheromones and larval olfactory cues), and abiotic and biotic factors influencing the efficacy of biological control agents. These new developments have created opportunities for further research into improving our risk assessment, monitoring, and integrated pest management capabilities.
Impact on The Structural, Morphological Properties, and Band Gap Tuning on Zinc Oxide Nanoparticles Substituted By Aluminum
Authors: Saxena Gaurav , Salmani Imran Ahmad , Khan Mohd Shahid , Khan Mohd Saleem
Published: August 2023

In the present study, we report the effect of Aluminum (Al) doping on the properties of zinc oxide (ZnO) nanoparticles. The sol-gel method was used to synthesize the pure and Al-doped ZnO nanoparticles. Al doping was done at three different concentrations 3%, 5%, and 7%. The presence of Al, Zn, and O is confirmed by EDX and XPS. The crystal structure and morphologic analysis of prepared nanoparticles using XRD, FESEM, and TEM-SAED techniques. An increase in the doping concentration has reduced the average crystallite size considerably in the range of 18–14 nm. The optical properties have been studied using UV–Vis spectrophotometer. The UV–Vis spectroscopic studies showed that Al was incorporated into the ZnO lattice as Al3+ due to the decreasing optical band gap of nanoparticles. The XPS and EDX analysis is done to confirm the elemental composition of the pure and Al-doped ZnO nanoparticles. The addition of a suitable doping agent will lead to the improvement of structural as well as optical properties. The variation in different properties due to the addition of Alas a dopant is also studied.
Ca2+ dynamics in interstitial cells: foundational mechanisms for the motor patterns in the gastrointestinal tract
Authors: Sanders Kenton M. , Drumm Bernard T. , Cobine Caroline A. , Baker Salah A.
Published: August 2023

The gastrointestinal (GI) tract displays multiple motor patterns that move nutrients and wastes through the body. Smooth muscle cells (SMCs) provide the forces necessary for GI motility, but interstitial cells, electrically coupled to SMCs, tune SMC excitability, transduce inputs from enteric motor neurons, and generate pacemaker activity that underlies major motor patterns, such as peristalsis and segmentation. The interstitial cells regulating SMCs are interstitial cells of Cajal (ICC) and PDGF receptor (PDGFR)α+ cells. Together these cells form the SIP syncytium. ICC and PDGFRα+ cells express signature Ca2+-dependent conductances: ICC express Ca2+-activated Cl− channels, encoded by Ano1, that generate inward current, and PDGFRα+ cells express Ca2+-activated K+ channels, encoded by Kcnn3, that generate outward current. The open probabilities of interstitial cell conductances are controlled by Ca2+ release from the endoplasmic reticulum. The resulting Ca2+ transients occur spontaneously in a stochastic manner. Ca2+ transients in ICC induce spontaneous transient inward currents and spontaneous transient depolarizations (STDs). Neurotransmission increases or decreases Ca2+ transients, and the resulting depolarizing or hyperpolarizing responses conduct to other cells in the SIP syncytium. In pacemaker ICC, STDs activate voltage-dependent Ca2+ influx, which initiates a cluster of Ca2+ transients and sustains activation of ANO1 channels and depolarization during slow waves. Regulation of GI motility has traditionally been described as neurogenic and myogenic. Recent advances in understanding Ca2+ handling mechanisms in interstitial cells and how these mechanisms influence motor patterns of the GI tract suggest that the term “myogenic” should be replaced by the term “SIPgenic,” as this review discusses.
“Extreme Nephroptosis”: A Kidney in the Inguinal Hernia
Authors: Shchukin Dmytro , Demchenko Vladyslav , Arkatov Andrii , Stetsyshyn Roman , Khareba Gennadii , Bielov Vladyslav
Published: August 2023

We present an extremely rare case of renal ptosis from the normal orthotopic position into the cavity of inguinal hernia in a 93-year-old male patient. The following clinical case was accompanied by renal insufficiency, which was associated with the obstruction of the right ureter in the hernial sac and the stenosis of the left renal artery. The differential diagnosis between nephroptosis and dystopic kidney was based on MDCT scan images, which demonstrated the length of the right renal artery to be more than 20 cm. The patient underwent percutaneous nephrostomy through the right inguinal area and was successfully followed up for two years. We also analyzed six similar clinical cases described in the literature. This disease has, thus far, been observed exclusively in elderly men with long-standing and large inguinal hernias. The most frequent complications in these patients include ureteral strangulation in the area of the hernial gate and renal failure.
Performance Evaluation of the Air-Type Photovoltaic-Thermal Collector Combined with Transverse Triangle Obstacle
Authors: Choi Hwi-Ung , Choi Kwang-Hwan
Published: August 2023

An air-type photovoltaic-thermal collector (PVTC) is a solar collector that generates heated air and electricity from the incident solar energy in a single system. Adding a heat transfer device to this PVTC improves its performance but also increases the power consumption of the fan. Nevertheless, the additional energy consumption has not yet been adequately considered in previous related studies. The current study investigates the performance of a novel air-type PVTC combined with a transverse triangle obstacle (TTO) under various geometric conditions of TTO, considering the energy consumption of the PVTC. The TTO, suggested by the authors, improves the thermal energy recovery capability in PVTC by increasing the air velocity and promoting a mix of heated and relatively cold air in a fluid field, different from the traditional heat transfer devices used in previous PVTCs. The relative height, length, and pitch of the TTO are selected as geometric conditions. The effect of these geometric conditions on performance improvement and the increase in power consumption of the PVTC are discussed in detail. The result showed that the relative height has a dominant effect on the energy generation and consumption of the PVTC, while the other factors have an inconsiderable effect. In addition, this research evaluates the daily performance of the PVTC with and without TTO. The relative height of 0.45 results in the highest daily performance. Compared to PVTC without TTO, the PVTC using a TTO with a relative height of 0.45 provides an increase of 22.93% and 2.79% in the thermal output and electrical output, respectively, with daily average thermal and electrical efficiencies of 39.04% and 17.01%, respectively. The thermal equivalent net energy output, considering both the energy generation and consumption of the PVTC, could also be improved by 7.8%.
Antimicrobial Susceptibility Patterns of Shigella Species among Children under Five Years of Age with Diarrhea in Selected Health Centers, Addis Ababa, Ethiopia
Authors: Ayele Basha , Mekonnen Zeleke , Sisay Tessema Tesfaye , Adamu Etsehiwot , Tsige Estifanos , Beyene Getenet
Published: August 2023

Background. Shigella and parasitic infections are common public health problems throughout the world. Shigellosis is an acute gastroenteritis infection and one of Ethiopia’s most common causes of morbidity and mortality, especially in children under five. High resistance rates to commonly used antibiotic agents have been documented in different locations in Ethiopia. Objective. This study aimed to characterize the antimicrobial features of the Shigella species isolated from children under five years of age with acute diarrhea in Addis Ababa, Ethiopia. Methods. Using a cross-sectional study, freshly passed fecal specimens were collected for intestinal parasite and bacterial isolation. Fecal samples for bacterial identification were placed immediately in Cary–Blair media and transported to the Ethiopian Public Health Institution (EPHI) laboratory. Antimicrobial susceptibility testing (AMST) was conducted using the disk diffusion method. Data were described using descriptive statistical tools. The association of independent and dependent variables was evaluated with logistic regression. A

P

value ≤0.05 was considered statistically significant. Results. The prevalence of intestinal parasites was 8.2% with seven different species. Among the 534 stool-cultured specimens, 47 (8.8%) were positive for Shigella species. Antimicrobial susceptibility testing (AMST) showed that 100%, 93.6%, 80.9%, 72.3%, and 57.5% were susceptible to norfloxacin, nalidixic acid, ciprofloxacin, gentamicin, and cefoxitin, respectively. However, 100% of the isolates were resistant to amoxicillin and erythromycin. More than 50% of the isolates were resistant to three and above antibiotics, while none of them were susceptible to all the antibiotics tested. All risk factors assessed did not show a statistically significant association with Shigella infection. Conclusion. The high levels of antibiotic resistance observed among the commonly prescribed antibiotics are alarming. The emerging resistance to ciprofloxacin and nalidixic acid signals a severe public health threat in the management of shigellosis. Raising awareness about resistance and educating health professionals, policymakers, and the public can help improve the quality of patient care and rational antibiotic use.
Modeling the Spread of COVID-19 Using Nonautonomous Dynamical System with Simplex Algorithm-Based Optimization for Time-Varying Parameters
Authors: Yotongyos Kevin , Sriyab Somchai
Published: August 2023

The

S
I
R
D
V

(Susceptible, Infected, Recovered, Death, Vaccinated) compartmental model along with time-varying parameters is used to model the spread of COVID-19 in the United States. Time-varying parameters account for changes in transmission rates, people’s behaviors, safety precautions, government regulations, the rate of vaccinations, and also the probabilities of recovery and death. By using a parameter estimation based on the simplex algorithm, the system of differential equations is able to match real COVID-19 data for infections, deaths, and vaccinations in the United States of America with relatively high precision. Autoregression is used to forecast parameters in order to forecast solutions. Van den Driessche’s next-generation approach for basic reproduction number agrees well across the entire time period. Analyses on sensitivity and elasticity are performed on the reproduction number with respect to transmission, exit, and natural death rates in order to observe the changes from a small change in parameter values. Model validation through the Akaike Information Criterion ensures that the model is suitable and optimal for modeling the spread of COVID-19.
Influence of Thermal Treatments, Extraction Methods, and Storage Conditions on Lycopene Content of Foods
Authors: Pathak Meenakshi , Sagar Narashans Alok
Published: August 2023

Lycopene is one of the main carotenoids in our daily diet. Fruit variety, environmental conditions, and maturity stage are the factors affecting the content of lycopene. Various processing techniques and extraction methods may also affect the level of lycopene in different food products, consequently changing the biological role of lycopene. The biological role of lycopene is to defend the tissues of tomatoes (conjugate bonds) and attract predators (red colour). Moreover, storage conditions also impact the lycopene content of fruits, vegetables, and their products. Efficient and novel technological interventions are required for stabilizing lycopene content during postharvest procedures, such as refrigeration, heating, extraction, and transportation. Therefore, the study of different crucial factors concerning the change in lycopene content is required. The present review explores the lycopene content of different food commodities and the effect of postharvest operations and processing techniques on lycopene content. It also highlights the storage impact on the concentration of lycopene which may be useful for future studies.
Solar Dish Concentrator: A Case Study at the Energy Center Rooftop
Authors: Marra Antonio , Santarelli Massimo , Papurello Davide
Published: August 2023

Concentrating solar technology plays a role, albeit a niche role compared to commercial solar systems (photovoltaics and thermal collectors). Within the context of sustainable development and within the green transition phase, it could be a respectable player. The main purpose of this study is to create and validate a model that approximates the temperature trend of a receiver installed in a CSP (concentrated solar plant). A method to approximate optical and thermal performance is discussed. The paraboloid installed in the Energy Center (Turin, Italy) was taken as a reference, creating a model that could simulate real operating conditions. The Monte Carlo (MC) method for ray tracing was adopted developing two models. The first model sets the maximum reflectivity of the paraboloid and neglects the loss of “limb darkening,” while the second one sets a reflectivity of 80%. Once the incident flux was obtained, the optical performance was analytically calculated and compared to the value provided by the manufacturer. The thermal performance was also studied, reproducing the dimensions of the receiver consisting of a sintered alumina tube placed at a focal distance from the paraboloid. Two configurations were analyzed: one neglecting the losses due to radiation and natural convection, the other one including the losses due to radiation and considering the atmospheric wind condition. Finally, the model was validated by comparing the obtained temperatures with those measured by thermocouples placed on the receiver. Analyzing two random days in the year 2020, an average error of 7% and 2% was obtained.
Pixel-Level Crack Detection and Quantification of Nuclear Containment with Deep Learning
Authors: Yu Jian , Xu Yaming , Xing Cheng , Zhou Jianguo , Pan Pai
Published: August 2023

Crack detection based on deep learning is an advanced technology, and many scholars have proposed many methods for the segmentation of pavement cracks. However, due to the difference of image specifications and crack characteristics, some existing methods are not effective in detecting cracks of containment. To quickly detect cracks and accurately extract crack quantitative information, this paper proposes a crack detection model, called MA_CrackNet, based on deep learning and a crack quantitative analysis algorithm. MA_CrackNet is an end-to-end model based on multiscale fusions that achieve pixel-level segmentation of cracks. Experimental results show that the proposed MA_CrackNet has excellent performance in the crack detection task of nuclear containment, achieving a precision, recall, F1, and mean intersection-over-union (mIoU) of 86.07%, 89.96%, 87.97%, and 89.19%, respectively, outperforming other advanced semantic segmentation models. The quantification algorithm automatically measures the four characteristic indicators of the crack, namely, the length of the crack, the area, the maximum width, and the mean width and obtains reliable results.
The IGF2BP3–COPS7B Axis Facilitates mRNA Translation to Drive Colorectal Cancer Progression
Authors: Tang Jing , Wang Shuoshuo , Weng Mingjiao , Guo Qingyu , Ren Lili , He Yan , Cui Zihan , Cong Mingqi , Qin Minglu , Yu Jia , Su Rui , Li Xiaobo
Published: August 2023

Many studies have provided valuable information about genomic and transcriptomic changes that occur in colorectal cancer. However, protein abundance cannot be reliably predicted by DNA alteration or mRNA expression, which can be partially attributed to posttranscriptional and/or translational regulation of gene expression. In this study, we identified increased translational efficiency (TE) as a hallmark of colorectal cancer by evaluating the transcriptomic and proteomic features of patients with colorectal cancer, along with comparative transcriptomic and ribosome-protected mRNA analysis in colon epithelial cells and colon cancer cells. COP9 signalosome subunit 7B (COPS7B) was among the key genes that consistently showed both significant TE increase and protein elevation without transcriptional alteration in colorectal cancer. Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) enhanced the TE of COPS7B mRNA to promote colorectal cancer growth and metastasis. COPS7B was found to be a component of the ribo-interactome that interacted with ribosomes to facilitate ribosome biogenesis and mRNA translation initiation. Collectively, this study revealed the proteomic features of colorectal cancer and highlighted elevated mRNA translation as a hallmark of colorectal cancer. The identification of the IGF2BP3–COPS7B axis underlying the increased protein synthesis rate in colorectal cancer provided a promising therapeutic target to treat this aggressive disease.

Significance:

Increased expression of COPS7B mediated by IGF2BP3 elevates the translational efficiency of genes enriched in mRNA translation and ribosome biogenesis pathways, promoting protein synthesis and driving progression in colorectal cancer.
Table S2 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
Authors: Lam Vi , Roleder Carly , Liu Tingting , Bruss Nur , Best Scott , Wang Xiaoguang , Phillips Tycel , Shouse Geoffrey , Berger Allison J. , Alinari Lapo , Wang Lili , Siddiqi Tanya , Pennock Nathan D. , Danilov Alexey V.
Published: August 2023

Table S2 shows fluorochrome-conjugated anti-mouse antibodies used for flow cytometry experiments
Supplementary Data Methods from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
Authors: Lam Vi , Roleder Carly , Liu Tingting , Bruss Nur , Best Scott , Wang Xiaoguang , Phillips Tycel , Shouse Geoffrey , Berger Allison J. , Alinari Lapo , Wang Lili , Siddiqi Tanya , Pennock Nathan D. , Danilov Alexey V.
Published: August 2023

Supplementary methods
Figure S1 from T Cell–intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia
Authors: Lam Vi , Roleder Carly , Liu Tingting , Bruss Nur , Best Scott , Wang Xiaoguang , Phillips Tycel , Shouse Geoffrey , Berger Allison J. , Alinari Lapo , Wang Lili , Siddiqi Tanya , Pennock Nathan D. , Danilov Alexey V.
Published: August 2023

Figure S1 shows CD3+ T cells were pre-treated with TAK-981 at the indicated doses for 1 h, followed by TCR stimulation and quantification of western blots of figure 1
Supplementary material and method from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Authors: Nagira Yoji , Nagira Morio , Nagai Ryohei , Nogami Wataru , Hirata Michinari , Ueyama Azumi , Yoshida Tetsuya , Yoshikawa Mai , Shinonome Satomi , Yoshida Hiroshi , Haruna Miya , Miwa Hiroto , Chatani Natsumi , Ohkura Naganari , Wada Hisashi , Tanaka Hidekazu
Published: August 2023

Supplementary Information
Supplementary Figure Legends from Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures
Authors: Chang Stephen H. , Ice Ryan J. , Chen Michelle , Sidorov Maxim , Woo Rinette W.L. , Rodriguez-Brotons Aida , Jian Damon , Kim Han Kyul , Kim Angela , Stone David E. , Nazarian Ari , Oh Alyssia , Tranah Gregory J. , Nosrati Mehdi , de Semir David , Dar Altaf A. , Desprez Pierre-Yves , Kashani-Sabet Mohammed , Soroceanu Liliana , McAllister Sean D.
Published: August 2023

Text of Supplementary Figure Legends
Figure S5 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Authors: Nagira Yoji , Nagira Morio , Nagai Ryohei , Nogami Wataru , Hirata Michinari , Ueyama Azumi , Yoshida Tetsuya , Yoshikawa Mai , Shinonome Satomi , Yoshida Hiroshi , Haruna Miya , Miwa Hiroto , Chatani Natsumi , Ohkura Naganari , Wada Hisashi , Tanaka Hidekazu
Published: August 2023

In vivo anti-tumor activity of S-531011 in CT26.WT or EMT6 tumor-bearing mice model.
Supplementary Data Figure S2 from Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures
Authors: Chang Stephen H. , Ice Ryan J. , Chen Michelle , Sidorov Maxim , Woo Rinette W.L. , Rodriguez-Brotons Aida , Jian Damon , Kim Han Kyul , Kim Angela , Stone David E. , Nazarian Ari , Oh Alyssia , Tranah Gregory J. , Nosrati Mehdi , de Semir David , Dar Altaf A. , Desprez Pierre-Yves , Kashani-Sabet Mohammed , Soroceanu Liliana , McAllister Sean D.
Published: August 2023

Figure S2
Figure S3 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Authors: Nagira Yoji , Nagira Morio , Nagai Ryohei , Nogami Wataru , Hirata Michinari , Ueyama Azumi , Yoshida Tetsuya , Yoshikawa Mai , Shinonome Satomi , Yoshida Hiroshi , Haruna Miya , Miwa Hiroto , Chatani Natsumi , Ohkura Naganari , Wada Hisashi , Tanaka Hidekazu
Published: August 2023

Concentration of S-531011 in serum and tumor after a single intravenous administration of S-531011 in CT26.WT tumor-bearing hCCR8 KI mice.
Supplementary Data Figure S1 from Pan-Cancer Pharmacogenomic Analysis of Patient-Derived Tumor Cells Using Clinically Relevant Drug Exposures
Authors: Chang Stephen H. , Ice Ryan J. , Chen Michelle , Sidorov Maxim , Woo Rinette W.L. , Rodriguez-Brotons Aida , Jian Damon , Kim Han Kyul , Kim Angela , Stone David E. , Nazarian Ari , Oh Alyssia , Tranah Gregory J. , Nosrati Mehdi , de Semir David , Dar Altaf A. , Desprez Pierre-Yves , Kashani-Sabet Mohammed , Soroceanu Liliana , McAllister Sean D.
Published: August 2023

Figure S1
Figure S2 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Authors: Nagira Yoji , Nagira Morio , Nagai Ryohei , Nogami Wataru , Hirata Michinari , Ueyama Azumi , Yoshida Tetsuya , Yoshikawa Mai , Shinonome Satomi , Yoshida Hiroshi , Haruna Miya , Miwa Hiroto , Chatani Natsumi , Ohkura Naganari , Wada Hisashi , Tanaka Hidekazu
Published: August 2023

Generation of humanized CCR8 KI mice
Supplementary Table S3 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Authors: Meric-Bernstam Funda , Calvo Emiliano , Lee Keun Seok , Moreno Victor , Park Yeon Hee , Rha Sun Young , Chalasani Pavani , Zhong Wei , Zhou Li , Pirie-Shepherd Steven , Leung Abraham C.F. , Curigliano Giuseppe
Published: August 2023

Supplementary Table S3 shows the biomarker results
Supplementary Figure S1 from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Authors: Meric-Bernstam Funda , Calvo Emiliano , Lee Keun Seok , Moreno Victor , Park Yeon Hee , Rha Sun Young , Chalasani Pavani , Zhong Wei , Zhou Li , Pirie-Shepherd Steven , Leung Abraham C.F. , Curigliano Giuseppe
Published: August 2023

Supplementary Figure S1 shows the study design.
Data from T cell-intrinsic immunomodulatory effects of TAK-981 (subasumstat), a SUMO-activating enzyme inhibitor, in chronic lymphocytic leukemia
Authors: Lam Vi , Roleder Carly , Liu Tingting , Bruss Nur , Best Scott , Wang Xiaoguang , Phillips Tycel , Shouse Geoffrey , Berger Allison J. , Alinari Lapo , Wang Lili , Siddiqi Tanya , Pennock Nathan D. , Danilov Alexey V.
Published: August 2023

Abstract
Novel targeted agents used in therapy of lymphoid malignancies are recognized to have complex immune-mediated effects. Sumoylation, a posttranslational modification of target proteins by small ubiquitin-like modifiers (SUMO), regulates a variety of cellular processes indispensable in immune cell activation. Despite this, the role of sumoylation in T cell biology in context of cancer is not known. TAK-981 (subasumstat) is a small molecule inhibitor of the SUMO-activating enzyme (SAE) that forms a covalent adduct with an activated SUMO protein. Using T cells derived from patients with chronic lymphocytic leukemia (CLL), we demonstrate that targeting SAE activates type I interferon response. This is accompanied by largely intact T-cell activation in response to T-cell receptor engagement, with increased expression of CD69 and CD38. Furthermore, TAK-981 decreases Treg differentiation and enhances secretion of interferon-γ by CD4+ and CD8+ T-cells. These findings were recapitulated in mouse models, suggesting an evolutionarily conserved mechanism of T cell activation regulated by SUMO modification. Relevant to the consideration of TAK-981 as an effective agent for immunotherapy in hematological malignancies, we demonstrate that the downstream impact of TAK-981 administration is enhancement of the cytotoxic function of CD8+ T cells, thus uncovering immune implications of targeting sumoylation in lymphoid neoplasia.
Data from Pan-cancer pharmacogenomic analysis of patient-derived tumor cells utilizing clinically relevant drug exposures
Authors: Chang Stephen H. , Ice Ryan J. , Chen Michelle , Sidorov Maxim , Woo Rinette W.L. , Rodriguez-Brotons Aida , Jian Damon , Kim Han Kyul , Kim Angela , Stone David E. , Nazarian Ari , Oh Alyssia , Tranah Gregory J. , Nosrati Mehdi , de Semir David , Dar Altaf A. , Desprez Pierre-Yves , Kashani-Sabet Mohammed , Soroceanu Liliana , McAllister Sean D.
Published: August 2023

Abstract
As a result of tumor heterogeneity and solid cancers harboring multiple molecular defects, precision medicine platforms in oncology are most effective when both genetic and pharmacological determinants of a tumor are evaluated. Expandable patient-derived xenograft (PDX) mouse tumor and corresponding PDX culture (PDXC) models recapitulate many of the biological and genetic characteristics of the original patient tumor, allowing for a comprehensive pharmacogenomic analysis. Here, the somatic mutations of 23 matched patient tumor and PDX samples encompassing four cancers were first evaluated using next generation sequencing (NGS). 19 antitumor agents were evaluated across 78 patient-derived tumor cultures using clinically relevant drug exposures. A binarization threshold sensitivity classification determined in culture (PDXC) was used to identify tumors that best respond to drug in vivo (PDX). Utilizing this sensitivity classification, logic models of DNA mutations were developed for 19 antitumor agents to predict drug response. We determined that the concordance of somatic mutations across patient and corresponding PDX samples increased as variant allele frequency (VAF) increased. Notable individual PDXC responses to specific drugs, as well as lineage-specific drug responses where identified. Robust responses identified in PDXC were recapitulated in vivo in PDX-bearing mice and logic modeling determined somatic gene mutation(s) defining response to specific antitumor agents. In conclusion, combining NGS of primary patient tumors, high-throughput drug screen (HTDS) using clinically relevant doses, and logic modeling, can provide a platform for understanding response to therapeutic drugs targeting cancer.
Data from Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model
Authors: Sharma Rupali , Earla Bhargav , Baidoo Kwamena E. , Zeiger Martha A. , Madigan James P. , Escorcia Freddy E. , Sadowski Samira M.
Published: August 2023

Abstract
Pancreatic neuroendocrine tumors (PNETs) express high levels of somatostatin receptor type 2 (SSTR2), a unique target for both tumor imaging and therapy. This surface expression is lost in metastatic high-grade PNETs, making patients ineligible for SSTR2-targeted 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT), and represents an unmet clinical need. Here, we aimed to restore SSTR2 expression through the reversal of inhibitory epigenetic gene silencing in order to improve tumor responsiveness to PRRT. We first assessed human SSTR2 promoter methylation and expression levels in 96 patient samples. We then used three NET cell lines (QGP-1, BON-1, GOT-1) with variable SSTR2 expression profiles for functional in vitro studies using histone deacetylase inhibitors (HDACis). Finally, the QGP-1 xenograft mouse model, with low basal SSTR2 expression, was used to assess the therapeutic efficacy of combined HDACi and 177Lu-DOTATATE therapies. We confirm that SSTR expression is decreased and correlates with SSTR2 promoter methylation in patients with high grade NETs. When exposed to HDACis, SSTR2 surface expression is increased in three NET cell lines in vitro. In an in vivo PNET xenograft model with low basal SSTR2 expression, our studies demonstrate significantly higher tumor uptake of SSTR2-targeted 177Lu-DOTATATE in animals pretreated with HDACis compared to controls. For the first time, we show that this higher tumor uptake results in significant anti-tumor response when compared to standard PRRT alone. These preclinical results provide a rationale for utilizing HDACi pretreatment to improve targeted radionuclide therapy in patients with SSTR2-negative, metastatic PNETs.
Data from Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With HER2-Expressing Solid Tumors: A Phase 1 Dose Escalation Study
Authors: Meric-Bernstam Funda , Calvo Emiliano , Lee Keun Seok , Moreno Victor , Park Yeon Hee , Rha Sun Young , Chalasani Pavani , Zhong Wei , Zhou Li , Pirie-Shepherd Steven , Leung Abraham CF. , Curigliano Giuseppe
Published: August 2023

Abstract
PF-06804103 is an anti-HER2 antibody-drug conjugate with auristatin payload. We evaluated its safety, tolerability, and antitumor activity in patients with advanced/unresectable or metastatic breast cancer and gastric cancer. This multicenter, open-label, first-in-human, phase 1 study (NCT03284723) comprised dose escalation (P1) and dose expansion (P2). In P1, adults with HER2+ breast or gastric cancer received PF-06804103 0.15–5.0 mg/kg intravenously once/21 days (Q3W); in P2, patients with HER2+ or HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ hybridization [ISH]−) breast cancer received 3.0 or 4.0 mg/kg Q3W. The primary endpoints were dose-limiting toxicities (DLTs) and safety (P1), and objective response rate (ORR) assessed using RECIST v1.1 (P2). Ninety-three patients enrolled in P1 (n=47: HER2+ gastric cancer=22, HER2+ breast cancer=25) and P2 (n=46: HER2+ breast cancer=19, hormone receptor [HR]+ HER2-low breast cancer=27) received PF-06804103. Four patients (3.0- and 4.0-mg/kg groups, n=2 each) had DLTs (mostly Grade 3). Safety and efficacy results showed a dose–response relationship. Adverse events leading to treatment discontinuation (44/93, 47.3%) included neuropathy (11/93, 11.8%), skin toxicity (9/93, 9.7%), myalgia (5/93, 5.4%), keratitis (3/93, 3.2%), and arthralgia (2/93, 2.2%). Two (2/79, 2.5%) patients (P1, 4.0- and 5.0-mg/kg groups, n=1 each) achieved complete response; 21 (21/79, 26.6%) achieved partial response. In P2, ORR was higher in HER2+ compared with HR+ HER2-low breast cancer (3.0 mg/kg: 16.7% [2/12] vs 10.0% [1/10]; 4.0 mg/kg: 47.4% [9/19] vs 27.3% [3/11]). PF-06804103 demonstrated antitumor activity; however, adverse events led to discontinuation in 47.3% of patients. Safety and efficacy were dose-dependent.
Clinical trial registration: clinicaltrials.gov NCT03284723
Data from Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study
Authors: Meric-Bernstam Funda , Calvo Emiliano , Lee Keun Seok , Moreno Victor , Park Yeon Hee , Rha Sun Young , Chalasani Pavani , Zhong Wei , Zhou Li , Pirie-Shepherd Steven , Leung Abraham C.F. , Curigliano Giuseppe
Published: August 2023

Abstract
PF-06804103 is an anti-HER2 antibody–drug conjugate with auristatin payload. We evaluated its safety, tolerability, and antitumor activity in patients with advanced/unresectable or metastatic breast and gastric cancers. This multicenter, open-label, first-in-human, phase 1 study (NCT03284723) comprised dose escalation (P1) and dose expansion (P2). In P1, adults with HER2+ breast or gastric cancer received PF-06804103 0.15–5.0 mg/kg intravenously once/21 days (Q3W); in P2, patients with HER2+ or HER2-low (IHC 1+ or IHC 2+/ISH−) breast cancer received 3.0 or 4.0 mg/kg Q3W. The primary endpoints were dose-limiting toxicities (DLT) and safety (P1), and objective response rate (ORR) assessed using RECIST v1.1 (P2). Ninety-three patients enrolled in P1 (n = 47: HER2+ gastric cancer = 22, HER2+ breast cancer = 25) and P2 [n = 46: HER2+ breast cancer = 19, hormone receptor (HR)+ HER2-low breast cancer = 27] received PF-06804103. Four patients (3.0- and 4.0-mg/kg groups, n = 2 each) had DLTs (mostly Grade 3). Safety and efficacy results showed a dose–response relationship. Adverse events (AE) leading to treatment discontinuation (44/93, 47.3%) included neuropathy (11/93, 11.8%), skin toxicity (9/93, 9.7%), myalgia (5/93, 5.4%), keratitis (3/93, 3.2%), and arthralgia (2/93, 2.2%). Two (2/79, 2.5%) patients (P1, 4.0- and 5.0-mg/kg groups, n = 1 each) achieved complete response; 21 (21/79, 26.6%) achieved partial response. In P2, ORR was higher in HER2+ compared with HR+ HER2-low breast cancer [3.0 mg/kg: 16.7% (2/12) vs. 10.0% (1/10); 4.0 mg/kg: 47.4% (9/19) vs. 27.3% (3/11)]. PF-06804103 demonstrated antitumor activity; however, AEs led to discontinuation in 47.3% of patients. Safety and efficacy were dose-dependent.
Supplementary Table S6 from Association and Prediction Utilizing Craniocaudal and Mediolateral Oblique View Digital Mammography and Long-Term Breast Cancer Risk
Authors: Chen Simin , Tamimi Rulla M. , Colditz Graham A. , Jiang Shu
Published: August 2023

Supplementary Table S6: Hazards ratio of association among premenopausal women for baseline risk factors and breast cancer risk utilizing FULL-VPD
Supplementary Table S2 from Association and Prediction Utilizing Craniocaudal and Mediolateral Oblique View Digital Mammography and Long-Term Breast Cancer Risk
Authors: Chen Simin , Tamimi Rulla M. , Colditz Graham A. , Jiang Shu
Published: August 2023

Supplementary Table S2: Hazards ratio for association between baseline risk factors and breast cancer risk among postmenopausal women using MLO-VPD only.
Supplementary Figure S5 from Association and Prediction Utilizing Craniocaudal and Mediolateral Oblique View Digital Mammography and Long-Term Breast Cancer Risk
Authors: Chen Simin , Tamimi Rulla M. , Colditz Graham A. , Jiang Shu
Published: August 2023

Supplementary Figure S5: The proportional hazards assumption is deemed reasonable by checking the Schoenfeld residuals plot for CC-VPD.
Supplementary Figure S4 from Association and Prediction Utilizing Craniocaudal and Mediolateral Oblique View Digital Mammography and Long-Term Breast Cancer Risk
Authors: Chen Simin , Tamimi Rulla M. , Colditz Graham A. , Jiang Shu
Published: August 2023

Supplementary Figure S4: The linearity assumption is checked with Martingale residual plots.
Supplementary Table 5 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Authors: Moutafi Myrto , Koliou Georgia-Angeliki , Papaxoinis George , Economopoulou Panagiota , Kotsantis Ioannis , Gkotzamanidou Maria , Anastasiou Maria , Pectasides Dimitrios , Kyrodimos Efthymios , Delides Alexander , Giotakis Evangelos , Papadimitriou Nikolaos G. , Panayiotides Ioannis G. , Perisanidis Christos , Fernandez Aileen I. , Xirou Vasiliki , Poulios Christos , Gagari Eleni , Yaghoobi Vesal , Gavrielatou Niki , Shafi Saba , Aung Thazin Nwe , Kougioumtzopoulou Andromachi , Kouloulias Vassilis , Palialexis Konstantinos , Gkolfinopoulos Stavros , Strati Areti , Lianidou Evi , Fountzilas George , Rimm David L. , Foukas Periklis G. , Psyrri Amanda
Published: August 2023

Supplementary Table 5. Incidence of adverse events by maximum grade in the safety population.
Supplementary Table 2 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Authors: Moutafi Myrto , Koliou Georgia-Angeliki , Papaxoinis George , Economopoulou Panagiota , Kotsantis Ioannis , Gkotzamanidou Maria , Anastasiou Maria , Pectasides Dimitrios , Kyrodimos Efthymios , Delides Alexander , Giotakis Evangelos , Papadimitriou Nikolaos G. , Panayiotides Ioannis G. , Perisanidis Christos , Fernandez Aileen I. , Xirou Vasiliki , Poulios Christos , Gagari Eleni , Yaghoobi Vesal , Gavrielatou Niki , Shafi Saba , Aung Thazin Nwe , Kougioumtzopoulou Andromachi , Kouloulias Vassilis , Palialexis Konstantinos , Gkolfinopoulos Stavros , Strati Areti , Lianidou Evi , Fountzilas George , Rimm David L. , Foukas Periklis G. , Psyrri Amanda
Published: August 2023

Supplementary Table 2. Signature scores with significanlty changes pre- and post-Olaparib based treatment
Supplementary Figure 1 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Authors: Moutafi Myrto , Koliou Georgia-Angeliki , Papaxoinis George , Economopoulou Panagiota , Kotsantis Ioannis , Gkotzamanidou Maria , Anastasiou Maria , Pectasides Dimitrios , Kyrodimos Efthymios , Delides Alexander , Giotakis Evangelos , Papadimitriou Nikolaos G. , Panayiotides Ioannis G. , Perisanidis Christos , Fernandez Aileen I. , Xirou Vasiliki , Poulios Christos , Gagari Eleni , Yaghoobi Vesal , Gavrielatou Niki , Shafi Saba , Aung Thazin Nwe , Kougioumtzopoulou Andromachi , Kouloulias Vassilis , Palialexis Konstantinos , Gkolfinopoulos Stavros , Strati Areti , Lianidou Evi , Fountzilas George , Rimm David L. , Foukas Periklis G. , Psyrri Amanda
Published: August 2023

Supplementary Figure 1. Differentially expressed genes (Left) and gene signatures (Right) Cisplatin-Olaparib (A, B), Olaparib (C,D) and Durvalumab-Olaparib (E, F) arms in pre- and post-treatment samples. The significance (p-value, P and adjusted p-value, Padj) is represented relative to Fold Change (FC) in the x-axis.
A Case Report of Chronic Myelogenous Leukemia Presenting as Blastic Crisis with a T-Cell Acute Lymphoblastic Leukemia Phenotype: Awareness of a Rare Entity
Authors: Efstathopoulou Maria , Zoi Katerina , Siakantaris Marina P. , Koumbi Daphne , Zannou Anna , Triantafyllou Evangelia-Faidra , Tsourouflis Gerassimos , Lakiotaki Eleftheria , Vassilakopoulos Theodoros P. , Angelopoulou Maria K.
Published: August 2023

Chronic myelogenous leukemia at blast crisis with a T-cell phenotype (T-ALL CML-BC) at diagnosis, without any prior history of CML is extremely rare. After the introduction of tyrosine kinase inhibitors (TKIs), CML patients have a median survival comparable to general population and accelerated/blast crisis are rarely encountered. Most CML patients (80%) transform into acute myeloid leukemia and the rest into B-ALL. Anecdotal cases of Ph+ T-ALL, either de novo or in the context of CML-BC have been reported. Left shift in the blood, the presence of splenomegaly/extramedullary infiltration and the occurrence of BCR::ABL1 rearrangement in both the blastic population, as well as in the myeloid cell compartment are key points in differentiating de novo Ph+ T-ALL from T-ALL CML-BC. The latter is a rare entity, characterized by extramedullary disease, p210 transcript and clonal evolution. Lack of preceding CML does not rule out the diagnosis of T-ALL CML-BC. Prompt TKI treatment with ALL-directed therapy followed by allogeneic stem cell transplantation may offer long-term survival in this otherwise poor prognosis entity. In this paper, we describe a patient with T-ALL CML-BC at presentation, still alive 51 months after diagnosis and we offer a review of the literature on this rare subject. All clinical and laboratory features are provided in order to distinguish de novo Ph+ T-ALL from T-ALL CML-BC, underscoring the prognostic and therapeutic significance of such a differentiation.